(function(){ var content_array=["

關于勃林格殷格翰<\/b><\/p> \n

勃林格殷格翰致力于研究突破性療法，旨在變革生命，守護世世代代的健康。作為一家研發驅動的全球領先生物制藥企業，公司在醫療需求高度未得到滿足的領域通過創新展現價值。勃林格殷格翰自1885年成立以來一直是一家獨立的家族企業，始終著眼長遠發展。在人用藥品、動物保健和生物制藥合同生產三大業務領域，全球有超過5.2萬名員工服務逾130個地區。更多詳情，請訪問：www.boehringer-ingelheim.com<\/a><\/p> \n

本新聞稿由位于德國殷格翰的公司總部發布，旨在提供有關我們全球業務的信息。請知悉與已批準產品的批準狀態和說明書相關的信息可能因國家而異，我們開展業務的國家可能已經發布該主題的特定新聞稿。<\/p> \n

參考文獻<\/p> \n

\n
Richeldi L., et al<\/i>. Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4B<\/span>, in Patients with Idiopathic Pulmonary Fibrosis: a Phase 2 Trial. Presented at American Thoracic Society (ATS) International Conference Breaking News session on May 16<\/span> 2022.<\/li> \n
Pulmonary Fibrosis Types and Causes. American Lung Association. https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/pulmonary-fibrosis\/introduction\/types-causes-and-risk-factors<\/a>. [Accessed May 2022<\/span>].<\/li> \n
Symptoms. Pulmonary Fibrosis Foundation. https:\/\/www.pulmonaryfibrosis.org\/understanding-pff\/about-pulmonary-fibrosis\/symptoms<\/a>. [Accessed May 2022<\/span>].<\/li> \n
Nalysnyk L., et al<\/i>. Incidence and Prevalence of Idiopathic Pulmonary Fibrosis: Review of the Literature. Eur Respir Rev. 2012;21(126):355-361.<\/li> \n
Data on file. Boehringer Ingelheim. DOF OFEV.RES.IPF\/08\/11January2016. Worldwide Prevalence 2016.<\/li> \n
Other Types of Pulmonary Fibrosis. Pulmonary Fibrosis Foundation. https:\/\/www.pulmonaryfibrosis.org\/understanding-pff\/types-of-pulmonary-fibrosis\/other-types-of-pulmonary-fibrosis<\/a>. [Accessed May 2022<\/span>].<\/li> \n<\/ol>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>

<optgroup id="kgssg"></optgroup>

<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区